| Literature DB >> 29617499 |
Jenny Lourdes Rivas de Oliveira1, Magaly Arrais Dos Santos1, Renato Tambellini Arnoni1, Auristela Ramos1, Dorival Della Togna1, Samira Kaissar Ghorayeb1, Roberto Tadeu Magro Kroll1, Luiz Carlos Bento de Souza1.
Abstract
INTRODUCTION: Active infective endocarditis is associated with high morbidity and mortality. Surgery is indicated in high-risk conditions, and the main determinants of mortality in surgical treatment should be evaluated.Entities:
Mesh:
Year: 2018 PMID: 29617499 PMCID: PMC5873776 DOI: 10.21470/1678-9741-2017-0132
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Preoperative clinical characteristics of the sample.
| Variables | Total Population n=88 | ||
|---|---|---|---|
| Age, years | 50.86±16.15 | 0.001 | |
| Gender | Male | 58 (65.9%) | 0.68 |
| Female | 30 (34.1%) | ||
| BMI, kg/m2 | 24.86±3.72 | 0.43 | |
| SH | 13 (14.8%) | 0.001 | |
| DM | 17 (19.3%) | 0.35 | |
| CKD | 17 (19.3%) | 0.11 | |
| Prior heart surgery | 48 (54.5%) | 0.48 | |
| Interval between prior and new surgery | ≤ 1 year | 22 (45.8%) | 0.95 |
| > 1 year | 26 (54.2%) | ||
| IV drug users | 4 (4.5%) | 0.31 | |
| AF | 18 (20.5%) | 0.78 | |
| LVEF ≤50% | 19 (21.59%) | 0.21 | |
| PH≥50 mmHg | 39 (44.3%) | 0.32 | |
| NYHA | II | 38 (43.2%) | 0.84 |
| III | 41 (46.6%) | ||
| IV | 9 (10.2%) | ||
| EuroSCORE II | 8.9%±6.5% | 0.03 |
AF=atrial fibrillation; BMI=body mass index; CKD=chronic kidney disease; DM=diabetes mellitus; IV=intravenous; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; PH=pulmonary hypertension; SH=systemic hypertension
Fig. 1Survival curves of patients with active infective endocarditis undergoing surgical treatment.
Postoperative complications.
| Variable | Population | Death n=18 | ||
|---|---|---|---|---|
| total n=88 | Presence of variable | Absence of variable | ||
| Postoperative complication | 45 (51.1%) | 17 (37.78%) | 1 (2.32%) | 0.001 |
| Sepsis | 19 (21.6%) | 17 (89.47%) | 1 (1.44%) | 0.001 |
| Shock | 17 (19.3%) | 16 (94.12%) | 2 (2.81%) | 0.001 |
| AFRVR | 15 (17%) | __ | 18 (22.78%) | 0.133 |
| CHB | 5 (5.7%) | 2 (40%) | 16 (19.27%) | 0.211 |
| Ventricular arrhythmia | 4 (4.5%) | 1 (25%) | 17 (20.23%) | 0.791 |
| Permanent pacemaker | 3 (3.4%) | 1 (33.33%) | 17 (20%) | 0.465 |
| Septic pulmonary embolism | 1 (1.13%) | 1 (100%) | __ | 0.003 |
| Ischemic stroke | 1 (1.13%) | __ | 18 (15.66%) | 0.650 |
| Surgical site infection | 3 (3.4%) | __ | 18 (15.30%) | 0.449 |
AFRVR=atrial fibrillation with rapid ventricular response; CHB=complete heart block
Multivariate analysis of preoperative factors.
| Variable | HR | 95% CI | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Positive blood culture | 4.92 | 0.38 | 63.849 | 0.223 |
| Typical microorganism | 1.304 | 0.154 | 11.064 | 0.808 |
| CRP | 1.002 | 0.961 | 1.031 | 0.784 |
| Creatinine clearance | 0.978 | 0.958 | 0.998 | 0.035 |
| SH | 5.194 | 1.268 | 21.266 | 0.022 |
| Age | 0.997 | 0.951 | 1.046 | 0.915 |
CI=confidence interval; CRP=C-reactive protein; SH=systemic hypertension; HR=hazard ratio
Fig. 2Survival curves of patients with active infective endocarditis undergoing surgical treatment with and without typical microorganisms in their preoperative blood cultures.
Fig. 3Survival curves of patients with active infective endocarditis undergoing surgical treatment with total surgery times less than 435 minutes and with total surgery times greater than or equal to 435 minutes.
| Abbreviations, acronyms & symbols | |
|---|---|
| AF | = Atrial fibrillation |
| AFRVR | = Atrial fibrillation with rapid ventricular response |
| AIE | = Active infective endocarditis |
| BMI | = Body mass index |
| CI | = Confidence interval |
| CRP | = C-reactive protein |
| CKD | = Chronic kidney disease |
| DM | = Diabetes mellitus |
| HR | = Hazard ratio |
| IE | = Infective endocarditis |
| LVEF | = Left ventricular ejection fraction |
| PASP | = Pulmonary artery systolic pressure |
| PH | = Pulmonary hypertension |
| SH | = Systemic hypertension |
| Authors' roles & responsibilities | |
|---|---|
| JLRO | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| MAS | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| RTA | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| AR | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| DDT | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| SKG | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| RTMK | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| LCBS | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |